This week saw the passing of Janey Godley, a Scottish comedian, aged only 63.  She died of ovarian cancer having bravely documented her fight with the disease since her diagnosis in 2021.  Ovarian cancer is one of the most challenging cancers to detect and treat early. Known as the “silent killer” due to its subtle symptoms, ovarian cancer often goes undetected until it has progressed to a more advanced stage. For women, the stakes are high: early detection can significantly improve outcomes, while late-stage diagnosis often limits treatment options and reduces survival rates. Recent advances in biotechnology, particularly in home testing for biomarkers like CA125 proteins, offer promising avenues for early diagnosis, which could be a game-changer for those at risk of ovarian cancer. 

What Is Ovarian Cancer? 

Ovarian cancer originates in the ovaries, the small reproductive glands that produce eggs and female hormones. It is the fifth leading cause of cancer-related  deaths among women and has one of the highest mortality rates among gynaecological cancers. While ovarian cancer can develop in women of any age, it most commonly occurs after menopause. The symptoms are often vague—bloating, pelvic pain, and changes in bowel habits—making it difficult to distinguish from other, less severe conditions. 

The key to improving outcomes for ovarian cancer patients is early diagnosis. Unfortunately, only about 20% of ovarian cancer cases are detected at an early stage. When found early, around 94% of patients can survive longer than five years after diagnosis. However, for those diagnosed at an advanced stage, this rate drops significantly. Early detection strategies are therefore critical to reducing the impact of ovarian cancer. 

The Importance of Early Diagnosis in Ovarian Cancer 

Early diagnosis of ovarian cancer allows for a greater range of treatment options and more targeted therapies, often leading to improved survival rates. When ovarian cancer is caught in the early stages, patients may have access to less invasive treatments, such as localised surgery. They may even be able to avoid more aggressive therapies like chemotherapy.   

One of the main challenges in diagnosing ovarian cancer early is the lack of routine screening options. Unlike breast cancer, which can often be detected early through mammograms, ovarian cancer does not yet have a standardized screening method. Pelvic exams, transvaginal ultrasounds, and CA-125 blood tests are often used to monitor high-risk individuals, but these methods are not fool-proof and are typically employed only after symptoms arise or for those with a family history of cancer. 

The role of CA125 Proteins in Ovarian Cancer Detection 

Advances in research have identified several biomarkers linked to ovarian cancer, one of which is the CA125 protein family. CA125 proteins, also known as chemokine ligand proteins, are a group of molecules involved in immune cell signalling and can be present in higher levels in patients with ovarian cancer. By detecting elevated CA125 levels, healthcare professionals can better identify patients who may be in the early stages of ovarian cancer, even before symptoms arise. 

Scientists have found that CA125 proteins can be indicative of cancer cell activity and can, therefore, act as an early warning system for ovarian cancer. Testing for CA125 levels could allow for much earlier detection of cancer cells in the body, potentially even before they become symptomatic. This makes CA125 proteins an exciting target in the development of ovarian cancer screening tools. 

Home Testing for CA125 Proteins: A Promising Approach 

Home testing kits that monitor CA125 protein levels have begun to emerge as a promising development in ovarian cancer screening. These tests, designed to be user-friendly, allow individuals to monitor their CA125 protein levels over time. A significant elevation in CA125 levels might suggest further testing by a healthcare professional, giving women a chance to catch the disease before it progresses. 

Benefits of Home Testing for Ovarian Cancer: 

1. Accessibility: Home tests make it easier for women to regularly screen themselves without having to visit a doctor frequently.
2. Convenience: Testing at home reduces the stress and inconvenience of repeated clinical visits, especially for those who may be in rural areas.
3. 3. Early Warning: By providing a means for regular monitoring, home tests can act as an early warning system, prompting users to seek medical attention if their levels are elevated.

Potential Limitations and Considerations: 

Despite their promise, home tests for CA125 proteins are still in the early stages of research and development. Current limitations include: 

– Accuracy and Reliability: Home tests must be highly accurate to be effective. False positives or negatives could lead to undue stress or a false sense of security. At present CA125 tests are thought to be 80% reliable.   

– Guidance for Users: For effective use, women need to know what their results mean and what steps to take if they get an abnormal reading. 

– Follow-up Care: Elevated CA125 levels should always be followed up by a medical professional. Not all elevated levels are necessarily indicative of cancer. 

– Costs – home test kits are not currently provided on the NHS and must be purchased.   

– Women should not rely solely on CA125 test results but should be educated on the signs and symptoms of ovarian cancer 

What the Future Holds 

While home testing for CA125 proteins is still a developing technology, it represents a step forward in making ovarian cancer screening more accessible and proactive. If these tests become widely available and affordable, they could empower women to take control of their health, making early diagnosis more achievable and, ultimately, saving lives. 

The development of home tests for ovarian cancer biomarkers, like CA125 proteins, could reshape how we approach early diagnosis and treatment. These tools could make it possible for women around the world to monitor their health from the comfort of their homes. In the fight against ovarian cancer, such advancements are essential, as they offer hope for earlier detection, improved outcomes, and a brighter future for those at risk. 

Conclusion 

Ovarian cancer remains a serious health threat, but with increased awareness, research, and innovations in diagnostic tools, we are moving closer to effective early detection. Biomarkers like CA125 proteins and the advent of home testing hold significant promise for empowering women to take an active role in monitoring their health. For now, it’s essential for women to stay informed, advocate for themselves, and pursue regular medical check-ups, especially if they are at higher risk. With ongoing advancements, the silent nature of ovarian cancer may one day give way to a world where it is detected early, treated effectively, and ultimately prevented. 

More information

If you would like more information about ovarian cancer then please take a look at these sources for reliable information

NHS – Ovarian cancer – NHS

Cancer Research UK – Ovarian cancer | Cancer Research UK

Macmillan Cancer Support – Ovarian cancer | Macmillan Cancer Support

Target Ovarian Cancer  – Testing | Target Ovarian Cancer

Phoenix Health and Wellbeing is a charitable social enterprise based in Leeds, West Yorkshire. We offer support in the form of counselling, acupuncture and massage therapies to people who are referred to us by medical professionals, due to their chronic health issues and low incomes. By using our services you are helping us to continue with this life enhancing support.  

Find out more about our charity here or view our massage treatments and counselling services or make a booking 

Opening times:  

Monday to Thursday: 10.00 to 20.00 

Friday and Saturday: 10.00 to 16.00